PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 3,202 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 3,202 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $75.06, for a total transaction of $240,342.12. Following the completion of the transaction, the insider owned 70,373 shares of the company’s stock, valued at $5,282,197.38. This represents a 4.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.43, for a total value of $3,039,074.70.

PTC Therapeutics Trading Up 5.3%

Shares of NASDAQ PTCT traded up $3.98 during trading hours on Friday, reaching $78.57. The stock had a trading volume of 2,735,148 shares, compared to its average volume of 1,223,774. The firm has a 50-day moving average of $73.32 and a 200-day moving average of $59.78. The firm has a market cap of $6.31 billion, a price-to-earnings ratio of 9.18, a PEG ratio of 0.27 and a beta of 0.47. PTC Therapeutics, Inc. has a fifty-two week low of $35.95 and a fifty-two week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) earnings per share. On average, equities analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its position in shares of PTC Therapeutics by 101.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 236 shares in the last quarter. Optiver Holding B.V. increased its holdings in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares in the last quarter. Comerica Bank lifted its position in shares of PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 469 shares during the period. Quantbot Technologies LP boosted its stake in shares of PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 551 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 320 shares during the period.

Wall Street Analyst Weigh In

PTCT has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price objective on shares of PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday. TD Cowen upped their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Finally, Citigroup boosted their target price on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $76.00.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.